Novo Nordisk's stock has plummeted over 60%, while also arguably losing market share to Eli Lilly. Click here to find out why ...

Curiously, this is both good news and bad news for Novo Nordisk stock. On the good news front, it stands to reason that if Ozempic is already a popular product ... it's to make the most of it.

Novo Nordisk's Q1 results show a dramatic expansion in sales beyond the US. Nevertheless, issues remain, and its outlook for ...

and Novo Nordisk, as a market leader in diabetes, I believe it will be one of the companies to benefit the most from this expected market growth. Add price increases for NVO's products ...

Novo Nordisk NOVO.B3.59%increase; green up pointing triangle shares rallied Wednesday as investors breathed a sigh of relief after first-quarter earnings beat expectations and the company’s ...

One such example is Novo Nordisk (NYSE: NVO), the Denmark-based pharmaceutical leader whose shares are exchanging hands for just $60 each, and as recently as last July, traded in the mid-140s. Novo ...

Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply reduced price on several telehealth ...

Novo Nordisk (NYSE:NVO) specializes in the research, development, production, and distribution of pharmaceutical products ... the beginning of 2025, while popular AI stocks lost around 25%.

The US Food and Drug Administration seized fake Ozempic injections. This happened on April 9, 2025. Novo Nordisk warned about ...

Novo Nordisk (NYSE: NVO), the Danish drugmaker that's been riding high ever since it began putting out Ozempic and Wegovy GLP-1 injectables for treatment of diabetes and weight loss, got another shot ...